International Niemann–Pick Disease Alliance

Updates

  1. Mallinckrodt Reaches Agreement to Divest Experimental Drug Adrabetadex to Mandos, LLC

    Company plans to produce up to an additional two years’ supply of drug for eligible patients Agreement is subject to approval by U.S. Bankruptcy Court in Delaware Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational...

    Read story
  2. Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy

    Read story
  3. INPDA Spotlight on Fundación Niemann-Pick de España (FNP)

    Sometimes in such a big organisation as the INPDA, our various member groups can be overshadowed, but we want to show just how important each and every member group is in making the INPDA work. In the INPDA Spotlight this...

    Read story
  4. Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

    Read story
  5. Cyclo Therapeutics Inc: Update (13/4/21)

    Read story
  6. INPDA Spotlight on VML France Niemann Pick Group

    Sometimes in such a big organisation as the INPDA, our various member groups can be overshadowed, but we want to show just how important each and every member group is in making the INPDA work. In the INPDA Spotlight this...

    Read story
  7. Pfrieger’s Digest – 03/2021 Edition

    “Pfrieger’s Digest” is written by Frank Pfrieger of Niemann-Pick Selbsthiifegruppe (Germany) to provide an overview of the latest advances in Niemann-Pick disease based on recent scientific publications. Frank Pfrieger is group leader at the Institute of Cellular and Integrative Neurosciences in...

    Read story
  8. Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)

    100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement in at least 2 domains of the 17-domain NPC Severity Scale Trial data suggest that Trappsol® Cyclo™ overcomes the...

    Read story
  9. University College London begins preclinical studies to develop a treatment for Niemann Pick C disease with support from the Columbus Foundation

    Read story
  10. Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference

    – Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer Products Gainesville, FL – (Business wire) – March 12, 2021 — Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage...

    Read story

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

Think Again. Think NP-C

Join our international campaign to improve diagnosis of NP-C!